Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 May;8(3):444-63.
doi: 10.1038/mi.2014.131. Epub 2015 Feb 11.

Potential effector and immunoregulatory functions of mast cells in mucosal immunity

Affiliations
Review

Potential effector and immunoregulatory functions of mast cells in mucosal immunity

L L Reber et al. Mucosal Immunol. 2015 May.

Abstract

Mast cells (MCs) are cells of hematopoietic origin that normally reside in mucosal tissues, often near epithelial cells, glands, smooth muscle cells, and nerves. Best known for their contributions to pathology during IgE-associated disorders such as food allergy, asthma, and anaphylaxis, MCs are also thought to mediate IgE-associated effector functions during certain parasite infections. However, various MC populations also can be activated to express functional programs--such as secreting preformed and/or newly synthesized biologically active products--in response to encounters with products derived from diverse pathogens, other host cells (including leukocytes and structural cells), damaged tissue, or the activation of the complement or coagulation systems, as well as by signals derived from the external environment (including animal toxins, plant products, and physical agents). In this review, we will discuss evidence suggesting that MCs can perform diverse effector and immunoregulatory roles that contribute to homeostasis or pathology in mucosal tissues.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Schematic, highly simplified representation of the potential roles of MCs in airway chronic allergic inflammation and remodeling
Individuals not yet sensitized to environmental allergens do not have specific IgE to such allergens, and few MCs are present within the epithelium (left panel). During allergic sensitization, environmental antigens (Ag) are captured by APCs in the airway lumen or in the epithelium of the airway mucosa, and Ag-activated APCs mature and migrate to regional lymph nodes, where priming of T cells occurs (not shown). The presence of IL-4 or IL-13, which may be derived from a variety of potential cellular sources, induces T cells to become TH2 cells (right panel). In some cases, allergens also can reach APCs in the submucosa through damaged epithelium. Cytokines induced by epithelial damage (such as IL-33 and TSLP) can activate ILC2 cells, which secrete type 2 cytokines, such as IL-4 and IL-13. The Th2 environment promotes heavy-chain class switching from IgM or IgG to IgE for Ag-specific IgE production in B cells. IgE binds to FcεRI on MCs (and basophils) and sensitizes these cells to respond to subsequent Ag exposures. Ag-induced aggregation of IgE-bound FcεRI causes the prompt release of pre-stored MC mediators, including histamine and TNF, which can promote bronchoconstriction and, more slowly, fibroblast proliferation. FcεRI activation also induces the production and the release of de novo synthesized compounds, such as leukotrienes, prostaglandins, and pro-inflammatory cytokines (e.g., IL-5, IL-6, IL-8, IL-13, and TNF) and chemokines (not shown), that contribute to the development of local inflammation. Both soluble factors, such as IFN-γ, TSLP, IL-33, S1P, LPS (through PRRs) and cells present at the site, such as TH cells and various Treg cells (not shown), which can interact with OX40L on MCs, modulating IgE-dependent MC activation, or B cells, which can interact with CD40L on MCs, which may enhance B cell IgE production. At least one MC-secreted product, MCPT4 (not shown), can negatively regulate the inflammatory environment, in part through the degradation of IL-33. Repetitive exposure to specific Ag favors persistent inflammation (with large numbers of eosinophils, and with MCs appearing within the epithelium), goblet cell hyperplasia and increased mucus secretion, smooth muscle cell proliferation, increased vascular permeability (and increased numbers of blood vessels) and airway edema, thickening and remodeling. In some asthma subtypes, genetic or environmental factors, including pathogen-derived products, tissue damage, airway pollutants, and oxidative stress, may confer strong TH1 and/or TH17 signatures associated with large numbers of neutrophils at the site of inflammation. Studies in MC–knockin mice have indicated that some actions of MCs, such as increasing the number of epithelial goblet cells, can occur in a model of chronic allergic inflammation by MC–dependent mechanisms that do not require MC signaling through the FcεRIγ chain, whereas MCs must express both the FcεRIγ chain and the IFN-γ receptor 1 (IFN-γR1) to mediate substantial increases in lung eosinophils and neutrophils. Note: down-regulatory mechanisms that can be engaged in this setting, such as co-engagement by multivalent Ag of both FcεRI and FcγRIIb, or effects of regulatory T cell populations, are not shown. AhR, Aryl hydrocarbon receptor; Baso, basophils; Eos, eosinophils; FcεRI, high affinity receptor for IgE; ILC2, innate lymphoid cells type 2; Neu, neutrophils; PRR, pattern recognition receptor; TH, T helper; TSLP, thymic stromal lymphopoietin.
Figure 2
Figure 2. Schematic, highly simplified representation of the potential roles of MCs in food allergy and parasite infections
In the normal intestine, MCs can contribute to the homeostatic regulation of the epithelial barrier through chymase- (MCPT4-) dependent mechanisms and few MCs are present within the epithelium (left panel). During sensitization with food allergens (middle panel) or primary infections with parasites (right panel), antigens (Ag) are captured by APCs and Ag-activated APCs mature and migrate to regional lymph nodes, where priming of T cells occurs (not shown). The presence of IL-4 or IL-13, which may be derived from a variety of potential cellular sources, induces T cells to become TH2 cells. TH2 cells and ILC2 cells release IL-3 and IL-9 which promote expansion of mucosal MCs (MMCs), and some of these MMCs are found in the intestinal epithelium. IgE binds to FcεRI on MCs (and basophils) and sensitizes these cells to respond to subsequent Ag exposures. Ag-induced aggregation of IgE-bound FcεRI causes the prompt release of pre-stored MC mediators, including histamine which can promote vasodilatation and increased vascular permeability. FcεRI activation also induces the production and release of de novo synthesized compounds, such as leukotrienes, prostaglandins, and pro-inflammatory cytokines (such as IL-13) and chemokines (not shown). Such MC-derived products contribute to intestinal inflammation (including the recruitment and activation of neutrophils, basophils and eosinophils and other leukocytes), increased intestinal permeability and motility, and, in the case of parasite infections, worm expulsion. During food allergy, the activation of MCs also can promote diarrhea and, in some unfortunate individuals, anaphylaxis (not shown). IgG-Ag immune complexes can potentially modulate MC activation through Fcγ receptors (MCs express the activating receptor FcγRIII and the inhibitory receptor FcγRIIb). Macrophages, basophils and neutrophils are also activated by IgG-Ag immune complexes and release PAF, which is thought to contribute to diarrhea and anaphylaxis in food allergy. Note: down-regulatory mechanisms that can be engaged in these settings, such as co-engagement by multivalent Ag of both FcεRI and FcγRIIb, or effects of regulatory T cell populations, are not shown. Baso, basophils; Eos, eosinophils; FcεRI, high affinity receptor for IgE; FcγRs: receptors for IgGs; ILC2, innate lymphoid cells type 2; Neu, neutrophils; PAF, platelet-activating factor; PRR, pattern recognition receptor; TH2, T helper 2.

References

    1. Mekori YA, Metcalfe DD. Mast cells in innate immunity. Immunol Rev. 2000;173:131–140. - PubMed
    1. Metz M, Grimbaldeston MA, Nakae S, Piliponsky AM, Tsai M, Galli SJ. Mast cells in the promotion and limitation of chronic inflammation. Immunol Rev. 2007;217:304–328. - PubMed
    1. Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol. 2008;8(6):478–486. - PMC - PubMed
    1. Moon TC, St Laurent CD, Morris KE, Marcet C, Yoshimura T, Sekar Y, et al. Advances in mast cell biology: new understanding of heterogeneity and function. Mucosal Immunol. 2010;3(2):111–128. - PubMed
    1. Gurish MF, Austen KF. Developmental origin and functional specialization of mast cell subsets. Immunity. 2012;37(1):25–33. - PubMed

Publication types

MeSH terms